Fety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge

Louis F. Fries, Susan B. Dillon, James Hildreth, Ruth A. Karron, Ann W. Funkhouser, Carl J. Friedman, Christopher S. Jones, Vasantha G. Culleton, Mary Lou Clements

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

A recombinant influenza A vaccine (D protein), comprising a carboxy-terminal sequence from the hemagglutinin HA2 subunit of A/Puerto Rico/8/34 virus (H1N1, A/PR/34) fused to 81 ammo-terminal residues of the NS1 nonstructural protein, has previously protected mice against influenza A challenge by inducing H1N1/H2N2 cross-reactive cytotoxic T cells (CTL) without hemagglutination-inhibiting (HI) or neutralizing antibody. In our dose-escalating study, the vaccine was safe in humans and induced both IgG and T cell proliferative responses to D protein but little antibody to A/PR/34 or A/Kawasaki/8/86 (H1N1, A/KW/86) viruses. Among an additional group of A/KW/So-Seronegative volunteers immunized with 500 μg of D protein, none had a rise in serum HI or neutralizing antibody to A/KW/86, 20% had minimal IgG responses to A/KW/86 by EIA, and a minority had any increase in A/KW/86-specific CTL activity. However, viral shedding and clinical illness score were reduced in vaccinees relative to A/KW/86-seronegative unimmunized controls after intranasal challenge with wild-type A/KW/86. D protein immunization conferred significant protective immunity not currently explained by any of the immune parameters measured.

Original languageEnglish (US)
Pages (from-to)593-601
Number of pages9
JournalJournal of Infectious Diseases
Volume167
Issue number3
StatePublished - Mar 1993
Externally publishedYes

Fingerprint

H1N1 Subtype Influenza A Virus
Influenza Vaccines
Recombinant Proteins
Volunteers
Hemagglutination
Neutralizing Antibodies
Proteins
T-Lymphocytes
Immunoglobulin G
Virus Shedding
Puerto Rico
Synthetic Vaccines
Hemagglutinins
Human Influenza
Immunity
Immunization
Vaccines
Viruses
Antibodies
Serum

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Fety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. / Fries, Louis F.; Dillon, Susan B.; Hildreth, James; Karron, Ruth A.; Funkhouser, Ann W.; Friedman, Carl J.; Jones, Christopher S.; Culleton, Vasantha G.; Clements, Mary Lou.

In: Journal of Infectious Diseases, Vol. 167, No. 3, 03.1993, p. 593-601.

Research output: Contribution to journalArticle

Fries, LF, Dillon, SB, Hildreth, J, Karron, RA, Funkhouser, AW, Friedman, CJ, Jones, CS, Culleton, VG & Clements, ML 1993, 'Fety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge', Journal of Infectious Diseases, vol. 167, no. 3, pp. 593-601.
Fries, Louis F. ; Dillon, Susan B. ; Hildreth, James ; Karron, Ruth A. ; Funkhouser, Ann W. ; Friedman, Carl J. ; Jones, Christopher S. ; Culleton, Vasantha G. ; Clements, Mary Lou. / Fety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. In: Journal of Infectious Diseases. 1993 ; Vol. 167, No. 3. pp. 593-601.
@article{a5b64f74c96349fd97cd6b5bba89932b,
title = "Fety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge",
abstract = "A recombinant influenza A vaccine (D protein), comprising a carboxy-terminal sequence from the hemagglutinin HA2 subunit of A/Puerto Rico/8/34 virus (H1N1, A/PR/34) fused to 81 ammo-terminal residues of the NS1 nonstructural protein, has previously protected mice against influenza A challenge by inducing H1N1/H2N2 cross-reactive cytotoxic T cells (CTL) without hemagglutination-inhibiting (HI) or neutralizing antibody. In our dose-escalating study, the vaccine was safe in humans and induced both IgG and T cell proliferative responses to D protein but little antibody to A/PR/34 or A/Kawasaki/8/86 (H1N1, A/KW/86) viruses. Among an additional group of A/KW/So-Seronegative volunteers immunized with 500 μg of D protein, none had a rise in serum HI or neutralizing antibody to A/KW/86, 20{\%} had minimal IgG responses to A/KW/86 by EIA, and a minority had any increase in A/KW/86-specific CTL activity. However, viral shedding and clinical illness score were reduced in vaccinees relative to A/KW/86-seronegative unimmunized controls after intranasal challenge with wild-type A/KW/86. D protein immunization conferred significant protective immunity not currently explained by any of the immune parameters measured.",
author = "Fries, {Louis F.} and Dillon, {Susan B.} and James Hildreth and Karron, {Ruth A.} and Funkhouser, {Ann W.} and Friedman, {Carl J.} and Jones, {Christopher S.} and Culleton, {Vasantha G.} and Clements, {Mary Lou}",
year = "1993",
month = "3",
language = "English (US)",
volume = "167",
pages = "593--601",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Fety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge

AU - Fries, Louis F.

AU - Dillon, Susan B.

AU - Hildreth, James

AU - Karron, Ruth A.

AU - Funkhouser, Ann W.

AU - Friedman, Carl J.

AU - Jones, Christopher S.

AU - Culleton, Vasantha G.

AU - Clements, Mary Lou

PY - 1993/3

Y1 - 1993/3

N2 - A recombinant influenza A vaccine (D protein), comprising a carboxy-terminal sequence from the hemagglutinin HA2 subunit of A/Puerto Rico/8/34 virus (H1N1, A/PR/34) fused to 81 ammo-terminal residues of the NS1 nonstructural protein, has previously protected mice against influenza A challenge by inducing H1N1/H2N2 cross-reactive cytotoxic T cells (CTL) without hemagglutination-inhibiting (HI) or neutralizing antibody. In our dose-escalating study, the vaccine was safe in humans and induced both IgG and T cell proliferative responses to D protein but little antibody to A/PR/34 or A/Kawasaki/8/86 (H1N1, A/KW/86) viruses. Among an additional group of A/KW/So-Seronegative volunteers immunized with 500 μg of D protein, none had a rise in serum HI or neutralizing antibody to A/KW/86, 20% had minimal IgG responses to A/KW/86 by EIA, and a minority had any increase in A/KW/86-specific CTL activity. However, viral shedding and clinical illness score were reduced in vaccinees relative to A/KW/86-seronegative unimmunized controls after intranasal challenge with wild-type A/KW/86. D protein immunization conferred significant protective immunity not currently explained by any of the immune parameters measured.

AB - A recombinant influenza A vaccine (D protein), comprising a carboxy-terminal sequence from the hemagglutinin HA2 subunit of A/Puerto Rico/8/34 virus (H1N1, A/PR/34) fused to 81 ammo-terminal residues of the NS1 nonstructural protein, has previously protected mice against influenza A challenge by inducing H1N1/H2N2 cross-reactive cytotoxic T cells (CTL) without hemagglutination-inhibiting (HI) or neutralizing antibody. In our dose-escalating study, the vaccine was safe in humans and induced both IgG and T cell proliferative responses to D protein but little antibody to A/PR/34 or A/Kawasaki/8/86 (H1N1, A/KW/86) viruses. Among an additional group of A/KW/So-Seronegative volunteers immunized with 500 μg of D protein, none had a rise in serum HI or neutralizing antibody to A/KW/86, 20% had minimal IgG responses to A/KW/86 by EIA, and a minority had any increase in A/KW/86-specific CTL activity. However, viral shedding and clinical illness score were reduced in vaccinees relative to A/KW/86-seronegative unimmunized controls after intranasal challenge with wild-type A/KW/86. D protein immunization conferred significant protective immunity not currently explained by any of the immune parameters measured.

UR - http://www.scopus.com/inward/record.url?scp=0027459268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027459268&partnerID=8YFLogxK

M3 - Article

C2 - 8440931

AN - SCOPUS:0027459268

VL - 167

SP - 593

EP - 601

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -